Pakistan Uzbekistan Travel-only Hong Kong Malaysia New Zealand Turkey Soberana 02, is a conjugate vaccine developed by the Finlay Institute in Cuba. Full... 318 KB (19,351 words) - 20:00, 21 April 2024 |
for Soberana 02. On 20 August 2021, Cuba approved Soberana Plus as a booster after two doses of Soberana 02. On 23 September, Cuba approved Soberana Plus... 7 KB (575 words) - 13:21, 24 January 2024 |
FINLAY-FR-2, COVID-19 vaccine candidate, also known as SOBERANA-02, which followed the earlier SOBERANA-01, produced by the Finlay Institute, a Cuban epidemiological... 371 bytes (76 words) - 19:57, 18 July 2021 |
typhoid fever in many children under the age of five years. In 2021, Soberana 02, a conjugate COVID-19 vaccine developed in Cuba, was given emergency... 10 KB (1,108 words) - 08:35, 6 December 2023 |
EpiVacCorona, ZF2001, MVC-COV1901, Corbevax, the Sanofi–GSK vaccine, and Soberana 02 (a conjugate vaccine). Bimervax was approved for use as a booster vaccine... 192 KB (22,024 words) - 10:32, 9 May 2024 |
During the COVID-19 pandemic, Cuba developed two COVID-19 vaccines. Soberana 02 is produced by the Pasteur Institute of Iran and the Finlay Institute... 78 KB (9,169 words) - 12:41, 25 April 2024 |
response to fight against COVID-19, Finlay Institute has developed the Soberana 02. In March 2021, Vicente Vérez, director of the Finlay Institute, announced... 3 KB (187 words) - 16:06, 11 December 2023 |
Novavax, Razi Cov Pars, Sanofi–GSK, Sinopharm CNBG, Skycovione, Soberana 02, Soberana Plus, V-01, and ZF2001. one virus-like particle vaccine: CoVLP As... 98 KB (20,593 words) - 02:58, 8 March 2024 |